Teplizumab, a groundbreaking immunotherapy that can postpone the onset of type 1 diabetes symptoms by as much as three years, has been approved for rollout in the UK by the National Institute for Health and Care Excellence (NICE). The treatment, also known as Tzield, targets children from age eight and adults diagnosed with early-stage, symptom-free type 1 diabetes.
How Teplizumab Works
Around 400,000 people in the UK live with type 1 diabetes, a lifelong condition where the immune system destroys insulin-producing cells. Teplizumab requires only a single 14-day course administered via intravenous drip in a hospital setting. Each daily session lasts at least 30 minutes, starting with a lower dose that is gradually increased over the first few days. The therapy retrains the immune system to preserve these vital cells, delaying disease progression and improving quality of life.
Eligibility and Expected Impact
NICE anticipates that approximately 1,100 people will meet the criteria for teplizumab in its first year, with the number settling to around 820 eligible patients annually as the rollout progresses. Clinical trials have shown the therapy effectively delays the onset of symptoms, giving younger patients crucial time before they must manage the demanding daily realities of diabetes, including insulin injections and carbohydrate counting.
Expert Reactions
Dr Elizabeth Robertson, director of research at Diabetes UK, hailed the approval as a landmark moment. "Today's landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment. For the first time in 100 years, we are moving beyond insulin, with a medicine that targets the root cause of the condition," she said. "This is an extraordinary moment for celebration in the type 1 diabetes community, and represents a shift towards a future where type 1 diabetes can be prevented altogether."
Helen Knight, director of medicines evaluation at NICE, described the recommendation as "genuinely exciting." She added: "For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition."
Screening Programs Underway
To identify eligible patients, medical experts are running two major screening projects. The Early Surveillance for Autoimmune Diabetes (ELSA) study, backed by Diabetes UK and Breakthrough T1D, focuses on children aged two to 17. The companion T1DRA initiative evaluates adults between 18 and 70. Dr Robertson emphasized the importance of early detection: "Detecting type 1 diabetes early, before symptoms appear, is key to unlocking these benefits, and our focus now is ensuring fair and equitable access for everyone who is eligible."
Patient and Advocate Voices
Elena Boichak, from Newbury, enrolled her son Dima in the ELSA study when he was nine, discovering he had stage 2 type 1 diabetes. She said: "As a mother, the most valuable thing teplizumab has given us is time. Every month and every year that Dima can continue being a child without insulin injections, carb counting, and the daily burden of type 1 diabetes is incredibly precious. This recommendation means that other families across the UK may now have access to that same opportunity."
Karen Addington, chief executive of Breakthrough T1D, called the approval "an incredible moment for the type 1 community." She stated: "For the first time, we have an immunotherapy that can delay the onset of symptomatic type 1 diabetes. If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition. We now have a treatment that can help make that possible."
Future Outlook
Dr Robertson concluded: "We want a future where everyone with early-stage type 1 diabetes can benefit from immunotherapies. Through our long-term investment in world-class research, and partnership with the NHS and industry, we are working to make a national type 1 diabetes screening programme a reality."
